Ramon Salazar

Summary

Country: Spain

Publications

  1. ncbi [Gastrointestinal and pancreatic neuroendocrine tumors]
    Ramon Salazar
    , , L'Hospitalet de Llobregat, Barcelona,
    Med Clin (Barc) 127:227-31. 2006
  2. ncbi Rare functioning pancreatic endocrine tumors
    Ramon Salazar
    Department of Gastroenterology, Beaujon Hospital, Clichy, France
    Neuroendocrinology 84:189-95. 2006
  3. ncbi A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
    R Salazar
    Instituto Catalán de Oncología, L Hospitalet de Llobregat, Avda Gran Via 199 203, Barcelona, Spain
    Cancer Chemother Pharmacol 70:673-81. 2012
  4. ncbi Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer
    Ramon Salazar
    Department of Medical Oncology, Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Autovía Castelldefels, Barcelona, Spain
    Clin Transl Oncol 14:592-8. 2012
  5. ncbi Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer
    Ramon Salazar
    Institut Catal DOncologiaIDIBELL, LHospitalet Barcelona, Barcelona, Spain
    Drugs 71:841-52. 2011
  6. ncbi Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer
    Ramon Salazar
    Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Av Gran Vía 199 203, Barcelona, Spain 08907
    J Clin Oncol 29:17-24. 2011
  7. ncbi Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
    Ramon Salazar
    Instituto Catalán de Oncología, Ctra Gran Vía, S N, L Hospitalet de Llobregat, 08907, Barcelona, Spain
    Invest New Drugs 29:1406-13. 2011
  8. ncbi Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype
    Alvaro Aytes
    Translational Research Laboratory, Institut Català d Oncologia Institut d Investigació Biomèdica de Bellvitge IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Carcinog 51:746-53. 2012
  9. ncbi Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death
    Mireia Berdiel-Acer
    Laboratory of Translational Research, Institut Català d Oncologia IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
    Neoplasia 13:931-46. 2011
  10. ncbi Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function
    Beatriz Pardo
    Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Med Oncol 29:2240-50. 2012

Collaborators

Detail Information

Publications20

  1. ncbi [Gastrointestinal and pancreatic neuroendocrine tumors]
    Ramon Salazar
    , , L'Hospitalet de Llobregat, Barcelona,
    Med Clin (Barc) 127:227-31. 2006
  2. ncbi Rare functioning pancreatic endocrine tumors
    Ramon Salazar
    Department of Gastroenterology, Beaujon Hospital, Clichy, France
    Neuroendocrinology 84:189-95. 2006
  3. ncbi A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
    R Salazar
    Instituto Catalán de Oncología, L Hospitalet de Llobregat, Avda Gran Via 199 203, Barcelona, Spain
    Cancer Chemother Pharmacol 70:673-81. 2012
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of elisidepsin...
  4. ncbi Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer
    Ramon Salazar
    Department of Medical Oncology, Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Autovía Castelldefels, Barcelona, Spain
    Clin Transl Oncol 14:592-8. 2012
    ..A prospective phase II study was conducted to assess the clinical activity and tolerability of oxaliplatin, capecitabine, and radiotherapy (RT) for neoadjuvant therapy of stages II-III rectal cancer...
  5. ncbi Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer
    Ramon Salazar
    Institut Catal DOncologiaIDIBELL, LHospitalet Barcelona, Barcelona, Spain
    Drugs 71:841-52. 2011
    ..Results of ongoing trials of dual-targeted therapy combinations will define future therapies for advanced WDNET...
  6. ncbi Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer
    Ramon Salazar
    Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Av Gran Vía 199 203, Barcelona, Spain 08907
    J Clin Oncol 29:17-24. 2011
    ..This study aims to develop a robust gene expression classifier that can predict disease relapse in patients with early-stage colorectal cancer (CRC)...
  7. ncbi Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
    Ramon Salazar
    Instituto Catalán de Oncología, Ctra Gran Vía, S N, L Hospitalet de Llobregat, 08907, Barcelona, Spain
    Invest New Drugs 29:1406-13. 2011
    ..4 months. In conclusion, plitidepsin 2.4 mg/m(2) and carboplatin AUC = 5 min*mg/ml is a safe dose for future phase II studies evaluating the use of this combination in cancer patients potentially sensitive to platinum-based therapy...
  8. ncbi Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype
    Alvaro Aytes
    Translational Research Laboratory, Institut Català d Oncologia Institut d Investigació Biomèdica de Bellvitge IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Mol Carcinog 51:746-53. 2012
    ....
  9. ncbi Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death
    Mireia Berdiel-Acer
    Laboratory of Translational Research, Institut Català d Oncologia IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
    Neoplasia 13:931-46. 2011
    ..Therefore, the liver microenvironment induces more efficiently the aggressiveness of colorectal cancer cells than other matched microenvironments do but secondarily evokes cell death. Resistant cells displayed higher stemness capacity...
  10. ncbi Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function
    Beatriz Pardo
    Institut Català d Oncologia IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain
    Med Oncol 29:2240-50. 2012
    ..Stratification criteria based on baseline AP apparently did not segregate the patients according to their liver dysfunction degree. Antitumor activity was found in patients with pretreated ovarian cancer...
  11. ncbi Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms
    Albert Font
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Crta Canyet s n, 08916, Badalona, Barcelona, Spain
    Cancer Chemother Pharmacol 62:1075-83. 2008
    ....
  12. ncbi A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Ps Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Invest New Drugs 30:299-305. 2012
    ..A phase I study was performed in patients with advanced solid tumors to determine the maximum tolerated dose (MTD), establish a safety profile, and to evaluate pharmacokinetics and efficacy of the drug...
  13. ncbi A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors
    Margarita Majem
    Institut Catala D Oncologia Duran i Reynals, L Hospitalet de Llobregat, Spain
    J Liposome Res 19:261-6. 2009
    ..The recommended dose is 70 mg/m(2) with prophylactic antihistamines and corticoids to preempt allergic reaction...
  14. ncbi Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors
    Jaume Capdevila
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Target Oncol 4:287-96. 2009
    ..In this article we aim to review the recent development of the main molecules that target these proteins and have showed promising activity in the treatment of GEPNETs...
  15. ncbi Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors
    Beatriz Pardo
    Institut Català d Oncologia and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 14:1116-23. 2008
    ....
  16. ncbi Gene expression differences between colon and rectum tumors
    Rebeca Sanz-Pamplona
    Unit of Biomarkers and Susceptibility, Catalan Institute of Oncology, IDIBELL, and CIBERESP, Barcelona, Spain
    Clin Cancer Res 17:7303-12. 2011
    ..We conducted a molecular study based on gene expression data of tumors from colon and rectum to assess the degree of similarity between these cancer sites at transcriptomic level...
  17. ncbi PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts
    David G Mollevi
    Translational Research Laboratory, Institut Catala d Oncologia, Institut d Investigació Biomèdica de Bellvitge IDIBELL, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Mol Cancer 8:46. 2009
    ..We demonstrate that products secreted by CAFs trigger PRL-3 overexpression in cancer cells. Identification of these factors may contribute to new stroma-targeted therapies for desmoplastic tumours...
  18. ncbi Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Cancer Metastasis Rev 30:27-34. 2011
    ..In this article, we aim to review the recent development of the main molecules that target mTOR complex and have showed promising activity in the treatment of GEPNETs...
  19. ncbi Differences in patient postoperative and long-term outcomes between obstructive and perforated colonic cancer
    Sebastiano Biondo
    Department of Surgery, Colorectal Unit, University Hospital of Bellvitge, University of Barcelona, Barcelona, Spain
    Am J Surg 195:427-32. 2008
    ..The aim of this observational study was to analyze the differences between patients with obstructive and perforated colonic cancer who managed with emergency curative surgery...
  20. ncbi Gastroenteropancreatic neuroendocrine tumours
    Irvin M Modlin
    Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520 8062, USA
    Lancet Oncol 9:61-72. 2008
    ..Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics...